MedTrace Logo

Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents

NCT01691014 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 79

Last updated 2016-12-29

Study results available
· View outcomes & findings →

Summary

The rationale for this study is to further explore if development of antibodies against TNF-α blocking agents is associated with reduced clinical effect/worsened clinical outcome. An important aspect of the study is to carry out an exploratory analysis of the immunogenicity of the 4 recommended TNF-α blockers in the treatment of RA in Denmark, using the same cell-based assay.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

OTHER

non-interventional study

Study with 4 arms/groups with 36 patients per group. In total 144 patients.

OTHER

non-interventional study

Study with 4 arms/groups with 36 patients per group. In total 144 patients.

OTHER

non-interventional study

Study with 4 arms/groups with 36 patients per group. In total 144 patients.

OTHER

non-interventional study

Study with 4 arms/groups with 36 patients per group. In total 144 patients.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01691014 on ClinicalTrials.gov